Gilead secures new anti-cancer therapy in $4.9bn deal
02-03-2020
Gilead challenges US govt patents on HIV drug Truvada
22-08-2019
Sundry Photography / Shutterstock.com
Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis (PrEP) invalidated.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Gilead Sciences, HIV, PrEP, Patent Trial and Appeal Board, PTAB, Truvada, Descovy, US Patent and Trademark Office, Bernie Sanders, Alexandria Ocasio-Cortez
